Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.

Detalles Bibliográficos
Autores principales: Koba, Hayato, Yoneda, Taro, Kaneda, Tomoya, Ueda, Tsukasa, Kimura, Hideharu, Kasahara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537071/
https://www.ncbi.nlm.nih.gov/pubmed/33042544
http://dx.doi.org/10.1002/ccr3.3358
_version_ 1783590639064055808
author Koba, Hayato
Yoneda, Taro
Kaneda, Tomoya
Ueda, Tsukasa
Kimura, Hideharu
Kasahara, Kazuo
author_facet Koba, Hayato
Yoneda, Taro
Kaneda, Tomoya
Ueda, Tsukasa
Kimura, Hideharu
Kasahara, Kazuo
author_sort Koba, Hayato
collection PubMed
description The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.
format Online
Article
Text
id pubmed-7537071
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75370712020-10-07 Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series Koba, Hayato Yoneda, Taro Kaneda, Tomoya Ueda, Tsukasa Kimura, Hideharu Kasahara, Kazuo Clin Case Rep Case Reports The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice. John Wiley and Sons Inc. 2020-09-25 /pmc/articles/PMC7537071/ /pubmed/33042544 http://dx.doi.org/10.1002/ccr3.3358 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Koba, Hayato
Yoneda, Taro
Kaneda, Tomoya
Ueda, Tsukasa
Kimura, Hideharu
Kasahara, Kazuo
Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title_full Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title_fullStr Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title_full_unstemmed Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title_short Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
title_sort severe coronavirus disease 2019 (covid‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: case series
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537071/
https://www.ncbi.nlm.nih.gov/pubmed/33042544
http://dx.doi.org/10.1002/ccr3.3358
work_keys_str_mv AT kobahayato severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries
AT yonedataro severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries
AT kanedatomoya severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries
AT uedatsukasa severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries
AT kimurahideharu severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries
AT kasaharakazuo severecoronavirusdisease2019covid19pneumoniapatientstreatedsuccessfullywithacombinationoflopinavirritonavirplusfavipiravircaseseries

Ejemplares similares